APRE:NSD-Aprea Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.32

Change

-0.12 (-2.70)%

Market Cap

USD 0.09B

Volume

0.89M

Average Target Price

USD 16.83 (+289.66%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-0.16 (-0.10%)

USD64.10B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+3.97 (+1.83%)

USD56.20B 21.10 15.27
REGN Regeneron Pharmaceuticals, Inc

+13.48 (+2.80%)

USD51.55B 15.77 12.24
ALXN Alexion Pharmaceuticals, Inc

+2.25 (+1.45%)

USD34.14B 57.09 33.71
BNTX BioNTech SE

+8.12 (+6.12%)

USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.16 (+2.38%)

USD27.77B N/A N/A
SGEN Seagen Inc

+5.44 (+3.77%)

USD26.14B 42.79 34.88
RPRX Royalty Pharma plc

-0.47 (-1.12%)

USD25.57B 22.60 15.33
GMAB Genmab A/S

+0.31 (+0.89%)

USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing APRE

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.20% 34% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.20% 34% F 15% F
Trailing 12 Months  
Capital Gain -87.31% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -87.31% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 15,900.00% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15,900.00% 99% A+ 99% A+
Average Annual (5 Year Horizon)  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return 41.94% 68% D+ 64% D
Market Capitalization 0.09B 16% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.36 95% A 77% C+
Price / Cash Flow Ratio -2.25 17% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -53.04% 57% F 22% F
Return on Invested Capital -52.38% 47% F 16% F
Return on Assets -29.16% 44% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.30 59% F 48% F
Short Percent 25.29% 3% F 6% F
Beta -0.78 99% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector